• +1-646-491-9876
    • +91-20-67278686

    Search

    Herpes Labialis-Pipeline Review H1 2017

    Herpes Labialis-Pipeline Review H1 2017

    • Report Code ID: RW0001834334
    • Category Pharmaceuticals
    • No. of Pages 49
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2017, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

    Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 4, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Herpes Labialis (Oral Herpes) - Overview
    Herpes Labialis (Oral Herpes) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Herpes Labialis (Oral Herpes) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development
    AiCuris GmbH & Co KG
    Beech Tree Labs Inc
    Foamix Pharmaceuticals Ltd
    NanoViricides Inc
    Onxeo SA
    Shulov Innovative Science Ltd
    Vironova AB
    Herpes Labialis (Oral Herpes) - Drug Profiles
    acyclovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acyclovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aspidasept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    B-220 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BTL-TMLHSV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes simplex virus [type 1, 2] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pritelivir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Cold Sores - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    squaric acid dibutyl ester - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZEP-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Herpes Labialis (Oral Herpes) - Dormant Projects
    Herpes Labialis (Oral Herpes) - Discontinued Products
    Herpes Labialis (Oral Herpes) - Product Development Milestones
    Featured News & Press Releases
    Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
    Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada
    Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent
    Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants
    May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium
    Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis
    Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial
    Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig
    May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier
    Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure
    Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis
    Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting
    Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
    Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial
    Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Herpes Labialis (Oral Herpes) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs Inc, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H1 2017
    Herpes Labialis (Oral Herpes) - Pipeline by Vironova AB, H1 2017
    Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2017
    Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Herpes Labialis (Oral Herpes) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AiCuris GmbH & Co KG
    Beech Tree Labs Inc
    Foamix Pharmaceuticals Ltd
    NanoViricides Inc
    Onxeo SA
    Shulov Innovative Science Ltd
    Vironova AB

    Request for Sample

    Report Url https://www.reportsweb.com//herpes-labialis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//herpes-labialis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//herpes-labialis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments